JP2018518172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518172A5 JP2018518172A5 JP2017563914A JP2017563914A JP2018518172A5 JP 2018518172 A5 JP2018518172 A5 JP 2018518172A5 JP 2017563914 A JP2017563914 A JP 2017563914A JP 2017563914 A JP2017563914 A JP 2017563914A JP 2018518172 A5 JP2018518172 A5 JP 2018518172A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- arenavirus
- virus vector
- configuration
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712891 Arenavirus Species 0.000 claims description 408
- 239000013598 vector Substances 0.000 claims description 235
- 239000000427 antigen Substances 0.000 claims description 182
- 102000036639 antigens Human genes 0.000 claims description 182
- 108091007433 antigens Proteins 0.000 claims description 182
- 241000701806 Human papillomavirus Species 0.000 claims description 137
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 120
- 239000013603 viral vector Substances 0.000 claims description 115
- 239000012634 fragment Substances 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 93
- 230000000890 antigenic effect Effects 0.000 claims description 87
- 108090000623 proteins and genes Proteins 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 59
- 241000700605 Viruses Species 0.000 claims description 51
- 229960005486 vaccine Drugs 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 49
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 208000015181 infectious disease Diseases 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 33
- 230000002458 infectious effect Effects 0.000 claims description 33
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 32
- 101710132595 Protein E7 Proteins 0.000 claims description 29
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 28
- 101710132594 Protein E6 Proteins 0.000 claims description 25
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 18
- 201000010153 skin papilloma Diseases 0.000 claims description 18
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 231100000590 oncogenic Toxicity 0.000 claims description 17
- 230000002246 oncogenic effect Effects 0.000 claims description 17
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 15
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 10
- 208000000260 Warts Diseases 0.000 claims description 10
- 206010059313 Anogenital warts Diseases 0.000 claims description 9
- 241000701022 Cytomegalovirus Species 0.000 claims description 9
- 241000711549 Hepacivirus C Species 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 101710132637 Protein C2 Proteins 0.000 claims description 7
- 101710132593 Protein E2 Proteins 0.000 claims description 7
- 101710132611 Protein E3 Proteins 0.000 claims description 7
- 101710132596 Protein E4 Proteins 0.000 claims description 7
- 101710132597 Protein E5 Proteins 0.000 claims description 7
- 101710132701 Protein L1 Proteins 0.000 claims description 7
- 101710132697 Protein L2 Proteins 0.000 claims description 7
- 101710195626 Transcriptional activator protein Proteins 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 241000700721 Hepatitis B virus Species 0.000 claims description 6
- 230000005867 T cell response Effects 0.000 claims description 6
- 208000021145 human papilloma virus infection Diseases 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 208000000907 Condylomata Acuminata Diseases 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 5
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 claims description 5
- 201000004201 anogenital venereal wart Diseases 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 4
- 241000579048 Merkel cell polyomavirus Species 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 4
- 206010034299 Penile cancer Diseases 0.000 claims description 4
- 102000017143 RNA Polymerase I Human genes 0.000 claims description 4
- 108010013845 RNA Polymerase I Proteins 0.000 claims description 4
- 102000009572 RNA Polymerase II Human genes 0.000 claims description 4
- 108010009460 RNA Polymerase II Proteins 0.000 claims description 4
- 206010038707 Respiratory papilloma Diseases 0.000 claims description 4
- 230000002457 bidirectional effect Effects 0.000 claims description 4
- 201000006958 oropharynx cancer Diseases 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 3
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 3
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 3
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 3
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 3
- 208000037581 Persistent Infection Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 108010077753 type II interferon receptor Proteins 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 108020004635 Complementary DNA Proteins 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 230000010415 tropism Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 102100039793 E3 ubiquitin-protein ligase RAG1 Human genes 0.000 claims 2
- 101000744443 Homo sapiens E3 ubiquitin-protein ligase RAG1 Proteins 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010053177 Epidermolysis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 46
- 239000000203 mixture Substances 0.000 description 36
- 238000010276 construction Methods 0.000 description 25
- 241000712890 Junin mammarenavirus Species 0.000 description 24
- 108700026244 Open Reading Frames Proteins 0.000 description 22
- 230000002519 immonomodulatory effect Effects 0.000 description 22
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 17
- 101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 description 13
- 102000004082 Calreticulin Human genes 0.000 description 12
- 108090000549 Calreticulin Proteins 0.000 description 12
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000002163 immunogen Effects 0.000 description 12
- 230000028327 secretion Effects 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 7
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 3
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 3
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 3
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 3
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 description 3
- 102000002265 Human Growth Hormone Human genes 0.000 description 3
- 108010000521 Human Growth Hormone Proteins 0.000 description 3
- 239000000854 Human Growth Hormone Substances 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 101710192266 Tegument protein VP22 Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 108010028930 invariant chain Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104300A JP2022160401A (ja) | 2015-06-10 | 2022-06-29 | Ｈｐｖワクチン |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173805P | 2015-06-10 | 2015-06-10 | |
| US62/173,805 | 2015-06-10 | ||
| US201562254410P | 2015-11-12 | 2015-11-12 | |
| US62/254,410 | 2015-11-12 | ||
| US201662331158P | 2016-05-03 | 2016-05-03 | |
| US62/331,158 | 2016-05-03 | ||
| PCT/EP2016/063182 WO2016198531A2 (en) | 2015-06-10 | 2016-06-09 | Hpv vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104300A Division JP2022160401A (ja) | 2015-06-10 | 2022-06-29 | Ｈｐｖワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518172A JP2018518172A (ja) | 2018-07-12 |
| JP2018518172A5 true JP2018518172A5 (enExample) | 2020-04-02 |
| JP7098330B2 JP7098330B2 (ja) | 2022-07-11 |
Family
ID=56137292
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563914A Active JP7098330B2 (ja) | 2015-06-10 | 2016-06-09 | Ｈｐｖワクチン |
| JP2022104300A Pending JP2022160401A (ja) | 2015-06-10 | 2022-06-29 | Ｈｐｖワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104300A Pending JP2022160401A (ja) | 2015-06-10 | 2022-06-29 | Ｈｐｖワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10669315B2 (enExample) |
| EP (1) | EP3307308A2 (enExample) |
| JP (2) | JP7098330B2 (enExample) |
| CN (2) | CN107921117B (enExample) |
| AU (2) | AU2016274655B2 (enExample) |
| CA (1) | CA2987155A1 (enExample) |
| HK (1) | HK1246183A1 (enExample) |
| WO (1) | WO2016198531A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103993012B (zh) | 2007-12-27 | 2023-01-10 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| RS61993B1 (sr) | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| MA45209A (fr) * | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| WO2017076988A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| CN110167586B (zh) * | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| CN110719788A (zh) * | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| RU2020106730A (ru) * | 2017-07-14 | 2021-08-16 | Онкорус, Инк. | Инкапсулированные полинуклеотиды и способы их применения |
| EP3461497A1 (en) * | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| WO2019151760A1 (ko) * | 2018-02-02 | 2019-08-08 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
| CN108424925A (zh) * | 2018-03-07 | 2018-08-21 | 江苏润洁生物科技有限公司 | 一种治疗性hpv核酸疫苗 |
| CA3117924A1 (en) * | 2018-11-13 | 2020-05-22 | Oncorus, Inc. | Encapsulated polynucleotides and methods of use |
| JP7688576B6 (ja) * | 2018-11-28 | 2025-07-04 | ザ ジェネラル ホスピタル コーポレイション | 共生ウイルスに対するｔ細胞指向性抗がんワクチン |
| JP7125760B2 (ja) * | 2019-06-14 | 2022-08-25 | 国立研究開発法人理化学研究所 | 免疫系を賦活化する細胞および当該細胞を含む医薬組成物 |
| WO2020255023A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
| CN114981443A (zh) * | 2019-11-07 | 2022-08-30 | 巴塞尔大学 | 作为载体的沙粒病毒 |
| US20220409540A1 (en) * | 2019-11-15 | 2022-12-29 | Daiichi Sankyo Company, Limited | Nucleic acid lipid particle vaccine encapsulating hpv mrna |
| AU2021271860B2 (en) * | 2020-05-14 | 2025-06-05 | Inovio Pharmaceuticals, Inc. | Vaccines for recurrent respiratory papillomatosis and methods of using the same |
| IL298420A (en) | 2020-05-29 | 2023-01-01 | Hookipa Biotech Gmbh | Cancer treatment strategies using RNA virus vectors |
| MX2023011054A (es) | 2021-03-23 | 2023-11-22 | Hookipa Biotech Gmbh | Arenavirus utilizados en tratamientos del cáncer de próstata. |
| CN115820696A (zh) * | 2022-07-28 | 2023-03-21 | 怡道生物科技(苏州)有限公司 | 治疗性多价HPV mRNA疫苗及其制备方法 |
| AU2024274630A1 (en) * | 2023-05-22 | 2026-01-22 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| AU2024343172A1 (en) | 2023-09-15 | 2026-03-05 | Gilead Sciences, Inc. | Arenavirus formulations, methods and uses thereof |
| WO2025155938A1 (en) * | 2024-01-18 | 2025-07-24 | Aov Biopharma, Inc. | Vaccine for prevention and treatment of human papilloma virus related cancer |
| WO2025191169A1 (en) * | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
| CN118344491B (zh) * | 2024-05-03 | 2025-02-14 | 华中科技大学同济医学院附属同济医院 | 一种hpv16/18治疗性疫苗、制备方法和应用 |
| CN118599010B (zh) * | 2024-05-03 | 2025-06-27 | 武汉凯德基诺生物技术有限公司 | 一种hpv16/18/52治疗性疫苗、制备方法和应用 |
| TW202615662A (zh) * | 2024-09-10 | 2026-04-16 | 大陸商北京劑泰醫藥科技有限公司 | 一種hpv疫苗及其應用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US6869779B1 (en) * | 1998-08-27 | 2005-03-22 | Fuso Pharmaceutical Industries, Ltd. | Nucleic acid sequence for potentiating the expression of useful gene and method therefor |
| DK1820853T3 (da) * | 1999-04-06 | 2011-12-19 | Wisconsin Alumni Res Found | Rekombinant influenzavirus til vacciner og genterapi |
| CA2499837C (en) * | 2002-10-03 | 2013-12-03 | Wyeth Holdings Corporation | Human papillomavirus polypeptides and immunogenic compositions |
| JP2008521434A (ja) * | 2004-11-30 | 2008-06-26 | エーラス グローバル ティービー ワクチン ファウンデーション | 組換え二重鎖ＲＮＡヌクレオカプシド類（ｒｄｓＲＮｓ）の生成および産生に有用なバクテリア・パッケージング株およびそれらの利用 |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| CN103993012B (zh) * | 2007-12-27 | 2023-01-10 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| CN104159607A (zh) | 2012-01-24 | 2014-11-19 | 桑福德研究院/南达科他大学 | 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 |
| WO2013151731A1 (en) * | 2012-04-02 | 2013-10-10 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium for induction of cellular immune response |
| US8999925B2 (en) * | 2013-02-26 | 2015-04-07 | The Administrators Of The Tulane Educational Fund | Arenavirus inhibiting peptides and uses therefor |
| US9809801B2 (en) | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| RS61993B1 (sr) | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| US10342861B2 (en) | 2014-05-27 | 2019-07-09 | University Of Rochester | Arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| BR112017005744B1 (pt) | 2014-09-22 | 2023-11-28 | Regents Of The University Of Minnesota | "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo" |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| US10849969B2 (en) | 2015-10-23 | 2020-12-01 | Institut Pasteur | Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity |
| WO2017076988A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| WO2017190074A1 (en) | 2016-04-28 | 2017-11-02 | The University Of Chicago | Lymphangiogenesis for therapeutic immunomodulation |
| IL262963B2 (en) | 2016-05-18 | 2025-01-01 | Hookipa Biotech Gmbh | Trisegmented PICHINDE viruses as vaccine vectors |
| CN110167586B (zh) | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| CN110719788A (zh) * | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| WO2020255023A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
| CN114981443A (zh) | 2019-11-07 | 2022-08-30 | 巴塞尔大学 | 作为载体的沙粒病毒 |
| IL298420A (en) | 2020-05-29 | 2023-01-01 | Hookipa Biotech Gmbh | Cancer treatment strategies using RNA virus vectors |
-
2016
- 2016-06-09 HK HK18105733.1A patent/HK1246183A1/zh unknown
- 2016-06-09 CN CN201680046208.4A patent/CN107921117B/zh active Active
- 2016-06-09 US US15/580,964 patent/US10669315B2/en active Active
- 2016-06-09 EP EP16730302.3A patent/EP3307308A2/en active Pending
- 2016-06-09 AU AU2016274655A patent/AU2016274655B2/en active Active
- 2016-06-09 JP JP2017563914A patent/JP7098330B2/ja active Active
- 2016-06-09 WO PCT/EP2016/063182 patent/WO2016198531A2/en not_active Ceased
- 2016-06-09 CN CN202210614772.9A patent/CN115197965A/zh active Pending
- 2016-06-09 CA CA2987155A patent/CA2987155A1/en active Pending
-
2020
- 2020-04-30 US US16/863,456 patent/US11407790B2/en active Active
-
2021
- 2021-09-13 AU AU2021232660A patent/AU2021232660B2/en active Active
-
2022
- 2022-06-29 US US17/853,783 patent/US20230086859A1/en not_active Abandoned
- 2022-06-29 JP JP2022104300A patent/JP2022160401A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230086859A1 (en) | Hpv vaccines | |
| JP6606571B2 (ja) | 治療用ｈｐｖ１６ワクチン | |
| JP6470872B2 (ja) | 治療用ｈｐｖ１８ワクチン | |
| Eiben et al. | Cervical cancer vaccines: recent advances in HPV research | |
| CN104039833B (zh) | 针对hpv的疫苗 | |
| Shi et al. | Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses | |
| JP2007507207A5 (enExample) | ||
| CN101426811A (zh) | 基于hpv-16的乳头瘤病毒疫苗 | |
| TW201941786A (zh) | 一種新型多價hpv 疫苗成份 | |
| JP2024545087A (ja) | Ｃｃｌ１１の用途 | |
| Villa | Vaccines against papillomavirus infections and disease | |
| US20050118139A1 (en) | Vaccine using papilloma virus e proteins delivered by viral vector | |
| Rollman et al. | HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses | |
| US20250041399A1 (en) | Cmv-based human papillomavirus vaccines | |
| Deng et al. | The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro | |
| AU3521499A (en) | Medicament for preventing or treating papilloma virus-specific tumors | |
| Im et al. | Prevention of cervical cancer with vaccines | |
| Poláková | Genová imunoterapie nádoru: DNA vakcíny proti HPV16 | |
| HK40082300A (en) | Hpv vaccines | |
| Villa | Vacunas contra el virus del papiloma humano y cáncer cervical invasor | |
| Devaraj et al. | DEVELOPMENT OF HPV VACCINES | |
| Gillison et al. | DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA. |